Klotho terminates licensing deal for gamma-melanocortin MC1R rights

Greenland Mines Ltd

Mutual termination of Jan 28, 2023 licensing agreement with Teleost Biopharmaceuticals.
Licensed rights no longer core to Klotho's business and research plans.
No further obligations or liabilities between parties; confidentiality survives.
Agreement covered worldwide rights to develop gamma-melanocortin drugs targeting MC1R receptors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.